---
title: "Top 10 港股跌幅（6月27日）"
description: "香港中旅 (00308) 跌 25.63%，成交额 19.9 亿港元，年内累计涨 48%。 圣贝拉 (02508) 跌 25.57%，成交额 2.8 亿港元，年内累计跌 0.5%。 国泰君安国际 (01788) 跌 14.69%，成交额 65.6 亿港元，年内累计涨 174.5%。"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/246377283.md"
published_at: "2025-06-27T08:31:02.000Z"
---

# Top 10 港股跌幅（6月27日）

> 香港中旅 (00308) 跌 25.63%，成交额 19.9 亿港元，年内累计涨 48%。 圣贝拉 (02508) 跌 25.57%，成交额 2.8 亿港元，年内累计跌 0.5%。 国泰君安国际 (01788) 跌 14.69%，成交额 65.6 亿港元，年内累计涨 174.5%。

恒生指数跌 0.17%，年内累计涨 21.1%；恒生科技指数跌 0.07%，年内累计涨 19.5%。

香港中旅 (00308) 跌 25.63%，成交额 19.9 亿港元，年内累计涨 48%。

圣贝拉 (02508) 跌 25.57%，成交额 2.8 亿港元，年内累计跌 0.5%。

国泰君安国际 (01788) 跌 14.69%，成交额 65.6 亿港元，年内累计涨 174.5%。

### Related Stocks

- [00308.HK - 香港中旅](https://longbridge.com/zh-CN/quote/00308.HK.md)
- [02508.HK - 圣贝拉](https://longbridge.com/zh-CN/quote/02508.HK.md)
- [01788.HK - 国泰君安国际](https://longbridge.com/zh-CN/quote/01788.HK.md)
- [01167.HK - 加科思-B](https://longbridge.com/zh-CN/quote/01167.HK.md)
- [06160.HK - 百济神州](https://longbridge.com/zh-CN/quote/06160.HK.md)
- [09669.HK - 北森控股](https://longbridge.com/zh-CN/quote/09669.HK.md)
- [00568.HK - 山东墨龙](https://longbridge.com/zh-CN/quote/00568.HK.md)
- [01126.HK - 德林国际](https://longbridge.com/zh-CN/quote/01126.HK.md)
- [01541.HK - 宜明昂科-B](https://longbridge.com/zh-CN/quote/01541.HK.md)
- [09995.HK - 荣昌生物](https://longbridge.com/zh-CN/quote/09995.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| BOCOM International Holdings Company Sticks to Their Buy Rating for RemeGen Co. Ltd. Class H (9995) | In a report released yesterday, from BOCOM International Holdings Company maintained a Buy rating on RemeGen Co. Ltd. Cl | [Link](https://longbridge.com/zh-CN/news/273178637.md) |
| RemeGen Lifts Price Cap on Share Repurchase | RemeGen Lifts Price Cap on Share Repurchase | [Link](https://longbridge.com/zh-CN/news/272783447.md) |
| JPM 26: Day 1 – drug prices and policy changes drive the agenda | At the 2026 J.P. Morgan Healthcare conference, discussions centered on drug pricing and regulatory changes, with a notab | [Link](https://longbridge.com/zh-CN/news/272392833.md) |
| Shandong Molong Forecasts 2025 Return to Profit on Overseas Growth and Cost Controls | Shandong Molong Petroleum Machinery (HK:0568) forecasts a return to profit in 2025, projecting a net profit of RMB 4-6 m | [Link](https://longbridge.com/zh-CN/news/273987310.md) |
| China's RemeGen Jumps by Limit After Granting AbbVie Novel Cancer Drug Rights in Up to USD5.6 Billion Deal | Shares of RemeGen surged by their daily limit in Shanghai after granting AbbVie exclusive global rights to its cancer dr | [Link](https://longbridge.com/zh-CN/news/272373268.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。